Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | MME | P08473 | 4/20 | 0.45 |
| ▸ | ACE | P12821 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | BCL2 | P10415 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | DCLRE1A | Q6PJP8 | 1/20 | 0.40 |
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL456713 | 0.86 | ESR2 (0.50) | ESR2MMEACECYP1A2ERCC5 | |
| SCHEMBL12603775 | 0.86 | AHR (0.50) | CYP1A2ERCC5FEN1AHR | |
| SCHEMBL19323707 | 0.84 | AKR1C2 (0.45) | AKR1C2AKR1C1AHRHPGD | |
| SCHEMBL455298 | 0.84 | ESR2 (0.47) | ESR2CYP1A2ERCC5FEN1BCL2 | |
| SCHEMBL12603776 | 0.82 | SCN9A (0.42) | PTGS2SMN1; SMN2NR1H2AHR | |
| SCHEMBL6308178 | 0.82 | ESR2 (0.53) | ESR2MMEACECYP1A2ERCC5 | |
| SCHEMBL30380433 | 0.81 | DCLRE1A (0.47) | CYP1A2BCL2PTGS2SMN1; SMN2L3MBTL1 | |
| SCHEMBL28992451 | 0.81 | DCLRE1A (0.47) | CYP1A2BCL2PTGS2SMN1; SMN2L3MBTL1 | |
| SCHEMBL12653047 | 0.81 | CYP2A6 (0.47) | DHODH | |
| SCHEMBL18724270 | 0.80 | SCN9A (0.43) | PTGS2MAPTAHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2614053-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2013-07-17 | — | — | EP | disclosed |
| WO-2012033225-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-03-15 | — | — | WO | disclosed |
| US-20110105463-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2011-05-05 | — | — | US | disclosed |
| US-4027041-A | Ethyl- and vinylbenzenes as antithrombotic agents | ELI LILLY AND COMPANY (US) | 1977-05-31 | — | — | US | disclosed |
| US-4024284-A | Ethyl- and vinylbenzenes as anti-inflammatory agents | ELI LILLY AND COMPANY (US) | 1977-05-17 | — | — | US | disclosed |
| US-3975542-A | Ethyl- and vinylbenzenes as antithromobiotic agents | ELI LILLY AND COMPANY (US) | 1976-08-17 | — | — | US | disclosed |
| US-3975543-A | Ethyl- and vinylbenzenes as anti-inflammatory agents | ELI LILLY AND COMPANY (US) | 1976-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105463-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | GPR52, CD22, CD4 | ESR2 83/4885MME 4193/4885ACE 3524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.